Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SVV-GFP is a recombinant Seneca Valley Virus (SVV-001) engineered to express Green Fluorescent Protein (GFP). It is an oncolytic picornavirus that exhibits high specificity for certain tumor types, particularly those with neuroendocrine features. In the context of glioblastoma, SVV-GFP is used as a diagnostic imaging agent to label infiltrative tumor cells in vivo following intravenous administration. This allows for real-time, image-guided fluorescent endomicroscopy during surgery to detect microscopic tumor clusters that are otherwise invisible to standard imaging modalities. The virus selectively infects and replicates in tumor cells, leading to the expression of GFP, which serves as a fluorescent marker for detection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SVV-GFP.